Results from the HERIZON-BTC-01 trial led to the approval of zanidatamab for patients with metastatic HER2-positive biliary tract cancer.
Approval Alert | Zanidatamab in Metastatic HER2-Positive Biliary Tract Cancer
Advertisement
Advertisement
Trending on CancerNetwork
1
Modifiable Risk Factors Suggest Potential for Improving Cancer Prevention
2
Dato-DXd Receives Priority Review in Unresectable/Metastatic TNBC
3
2026 Tandem Meetings: What’s the Latest Research in Multiple Myeloma?
4
Outlining Advances in AI For Breast Cancer Screening/Radiomics
5